Strata Critical Medical (SRTA) reported second-quarter 2026 revenue of $72.5 million, up 60.7% from $45.1 million a year earlier. The company reported a net loss from continuing operations of $10.5 million, or 14.5% of revenue.
The company said clinical revenue rose 22.6% sequentially to $24.3 million, while logistics revenue increased 6.9% year over year to $48.2 million. Strata also updated its 2026 revenue outlook to $285 million to $295 million.
- Q2 2026 total revenue was $72.5 million, compared with $45.1 million in Q2 2025.
- Net loss from continuing operations was $10.5 million in Q2 2026.
- Adjusted EBITDA was $7.9 million, with an adjusted EBITDA margin of 10.9%.
- Cash flow from operating activities was $5.7 million, and free cash flow was $2.9 million.
- Strata completed acquisitions of Louisville Perfusion Services, Heart and Lung Transplant National Recovery Program and Ohio Valley Perfusion Associates during the quarter.
- The company ended Q2 with $22.8 million in cash and short-term investments.
